Alnylam Pharmaceuticals SG&A Expense (Quarterly) Insights

Alnylam Pharmaceuticals Inc (ALNY)

152.74 +0.45 (+0.30%) USD | NASDAQ | May 09, 15:11

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2004. Upgrade now.

Date	Value
March 31, 2024	210.80M
December 31, 2023	198.12M
September 30, 2023	199.18M
June 30, 2023	214.69M
March 31, 2023	183.66M
December 31, 2022	210.34M
September 30, 2022	235.86M
June 30, 2022	169.98M
March 31, 2022	154.47M
December 31, 2021	186.38M
September 30, 2021	142.08M
June 30, 2021	145.32M
March 31, 2021	146.86M
December 31, 2020	166.29M
September 30, 2020	167.47M
June 30, 2020	127.90M
March 31, 2020	126.76M
December 31, 2019	156.28M
September 30, 2019	120.35M
June 30, 2019	112.77M
March 31, 2019	89.61M
December 31, 2018	108.69M
September 30, 2018	116.54M
June 30, 2018	84.68M
March 31, 2018	72.45M

Date	Value
December 31, 2017	67.46M
September 30, 2017	47.64M
June 30, 2017	45.78M
March 31, 2017	38.49M
December 31, 2016	27.88M
September 30, 2016	22.39M
June 30, 2016	17.99M
March 31, 2016	21.10M
December 31, 2015	17.23M
September 30, 2015	16.04M
June 30, 2015	14.62M
March 31, 2015	12.72M
December 31, 2014	14.18M
September 30, 2014	9.898M
June 30, 2014	11.52M
March 31, 2014	8.925M
December 31, 2013	8.333M
September 30, 2013	6.768M
June 30, 2013	5.784M
March 31, 2013	6.267M
December 31, 2012	10.17M
September 30, 2012	12.81M
June 30, 2012	11.23M
March 31, 2012	9.512M
December 31, 2011	10.67M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

112.77M

Minimum

Jun 2019

235.86M

Maximum

Sep 2022

168.78M

Average

166.88M

Median

SG&A Expense (Quarterly) Benchmarks